Lecture 3: Cystic Fibrosis Flashcards

1
Q

CF is an autosomal recessive disease. What does this mean?
A. Only mom carries the mutation
B. Only dad carries the mutation
C. Mom and dad both carry the mutation
D. Neither mom nor dad carries the mutation

A

CF is Progressive, life-shortening, genetic
disorder, Autosomal recessive.. originally from Europe/ whites (most common in white as well but effects all race!). orginally thought to be ped disease but can happen in all ages!
.
C! both mom and dad have to have that mutation but they do not have to have the disease..for each preg? 25%!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

CF Pathophysiology

A
  • Mutation of the cystic fibrosis transmembrane
    conductance regulator (CFTR) gene causes CFTR protein to dysfunction
  • Regulates chloride, sodium, bicarbonate transport across the cell membrane… dysfunction? mucus becomes thick and sticky
  • Over 2000 mutations: Different mutations result in different levels of CFTR function! not everyone will look the same! There are difference variance based on different gene mutation
    – F508del: Most common mutation… Protein misfolded, doesn’t reach cell surface
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Diagnosis of CF

A
  • Newborn screening
    – Immunoreactive trypsinogen
  • produced by pancreas
  • Sweat test
    – Sample of sweat is collected, and concentration of
    chloride is determined
    – Positive test is ≥ 60 mmol/L in children and adults
  • Chromosomal analysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Involved Organ Systems of CF… (general)

A
  • Gastrointestinal system
  • Hepatic system
  • Pulmonary system
  • Reproductive system
  • Musculoskeletal system
    .
    Involve of organs is related to where the CFTR gen is located!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Possible Patient Signs and Symptoms for CF

A
  • Poor growth or weight gain (due to the GI involvement! lack of nutrition absorbed)
  • Meconium ileus
  • Frequent, greasy, bulky stools or difficulty in bowel
    movements (due to not absorbing food well)
  • Frequent lung infections
  • Wheezing or shortness of breath
  • Persistent coughing, at times with sputum
  • Chronic sinusitis
  • Very salty-tasting skin (due to CFTR reg of salt!)
  • Male infertility
  • Nasal polyps
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pharmacological Therapy (2 main class)

A
  • Chronic therapy
  • Acute exacerbation therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Gastrointestinal System: Goals of therapy

A

– Control pancreatic insufficiency by providing adequate enzyme supplementation (cant absorb food and fat soluble vit!)
– Optimize growth and nutritional status
– Promote healthy bowel habits
– Maintain normal vitamin levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Gastrointestinal Tract Manifestations

A
  • Insufficient secretion of pancreatic enzymes
  • Fat-soluble vitamin malabsorption
  • Insulin deficiency
  • Intestinal obstruction
    – Meconium ileus
    – Distal intestinal obstruction syndrome (DIOS)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Pancreatic Insufficiency: Maldigestion of nutrients (symp)? - a Gastrointestinal Tract Manifestation

A
  • Symptoms: steatorrhea (greasy stool), frequent loose stools, flatulence, cramping, bloating, poor weight gain, sometimes constipation
  • Below age-related norms for both weight and height
  • Result of pancreatic enzymes deficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pancreatic Insufficiency: Treatment?

A

Pancreatic enzyme replacement therapy (PERT)!
.
– Creon®, Zenpep®, Pancreaze®, Ultresa™,Pertzye®, Viokace™
……. ALL Contain lipase, protease, amylase!
.
– Enzyme brands are not interchangeable
– Delayed release capsules: Containing enteric-coated microspheres or minitablets
– Products are porcine (pig) derived
.
- Delayed release capsule administration: Do not crush or chew contents, Capsules may be opened and added to small amount of room temperature, acidic food like applesauce. Consume immediately, follow with water, juice, formula, breast milk
- Regular release tablet administrations: Swallow tablets whole with sufficient liquid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Pancreatic Insufficiency: Treatment dosing

A

Dosing (no need to calc for exam! )
– Based on total body weight or fat ingested
– Dosed on lipase units
* 500-2,500 units/kg/meal
* 10,000 units/kg/day
* 4,000 units/gram of dietary fat/day
* Take with every meal and snack

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Pancreatic Insufficiency: Treatment Adverse events and monitoring

A

– Mucusal irritation
– Fibrosing colonopathy and colonic strictures reported at high doses (>6,000 lipase units/kg/meal): Diarrhea, Constipation, Abdominal pain
.
Monitoring parameters
– Stool fat content
– Abdominal symptoms
– Nutritional intake
– Growth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Another issue in CF (Gastrointestinal Tract Manifestations): Fat Soluble Vitamins and Nutritional Intake and Insulin Deficiency

A

1.) Fat soluble vitamin replacement
– A, D, E, K
– Doses higher compared to people without CF
.
2.) Energy intakes can be greater than standard for general population
– BMI >50-85% for age (need to take extra calories! healthy fat! )
– May require nutritional supplementation (Enteral feedings)
* Promotes healthy pulmonary function
.
3.) Cystic fibrosis-related diabetes
– Prevalence increases with age
– Associated with worse lung function, poorer nutritional status and increased pulmonary infections
– Distinct from type 1 and type 2 diabetes
– Treatment: Insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Another issue in CF: DIOS (intestine is obstructed): symp and therapy?- a Gastrointestinal Tract Manifestation

A
  • Symptoms
    – Cramping abdominal pain, poor appetite, abdominal distention
    .
  • Therapy
    – Electrolyte lavage solutions
  • Endpoint is passage of stool, symptom resolution
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Another issue in CF: Hepatic System/ Hepatic Manifestations. symp and tx?

A
  • Bile duct obstruction can lead to cirrhosis, portal hypertension
    .
  • Ursodeoxycholic acid
    – Controversial
    – Thought to reduce liver injury
    – 15-20 mg/kg/day; divided BID
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

CF issues (biggest reason why CF ppl die) : Pulmonary System manifestation, consequences, and goal?

A
  • Manifestations result from impaired mucociliary clearance resulting in accumulation of viscous mucus in airways
  • Consequences: Obstruction, Inflammation, Infection
  • Chronic rhinitis, sinusitis, nasal polyps
    .
    GOAL:
    Goal is to decrease the long-term rate of lung function decline
    – Airway clearance techniques (ACT)
    – Anti-inflammatory agents
    – Mucus alteration
    – Bronchodilators
    – Chronic antibiotics
17
Q

Pulmonary System: Airway clearance techniques (ACT)

A

– Improve ventilation, reduce accumulation of secretions
– Done at least BID
– Include: Chest/back percussion (you need someone else to pound on your back), Exercise, Percussion vest
– Bronchodilator pre-treatment

18
Q

Pulmonary System: Anti-inflammatory agents

A

1.) Ibuprofen
– Decreased rate of decline of FEV1
– 6-17 years with mild lung disease - FEV1 ≥ 60%
– Peak plasma concentrations of 50 -100 mg/L
– 20-30 mg/kg/dose given BID (v high dose! SE: GI issue)
- IT’S AN OPTION BUT WE DO NOT USE IT OFTEN AT ALL DUE TO SIDE EFFECT PROFILE!
.
2.) Azithromycin
– Unclear if anti-inflammatory effects are due to
antimicrobial and/or immunomodulatory mechanisms
– Slows decline in FEV1 in CF patients with Pseudomonas
– Decreased pulmonary exacerbation
– Dosing: Three times weekly!

19
Q

Pulmonary System: Mucus Alteration: 1. Pulmozyme

A

Pulmozyme®
– Aerosolized recombinant dornase alfa (DNase)
– Decreases viscosity of sputum
– Clinical trials show modest improvement: 3.2% FEV1 improvement, Decreased pulmonary exacerbation
– 2.5 mg nebulized once daily or BID
– AEs: hoarseness, voice alteration and pharyngitis (overall it is very well tolerated)
– Use select nebulizer, compressor
– Don’t mix with other medications in nebulizer

20
Q

Pulmonary System: Mucus Alteration: 2. Nebulized hypertonic saline

A

Nebulized hypertonic saline (3% - 7% salt water! like the ocean ! surfer does better cuz salt water!)
– Draws water into airways, improve mucus clearance
– 3-7% nebulized daily-BID
– Improved lung function, decrease exacerbations requiring antibiotics
– May cause bronchospasm, pre-treat with bronchodilator
– Hyper-Sal®, PulmoSal (v expensive! but works better for more severe cases!)™, Nebusal®
( PulmoSal™ buffered with sodium bicarb (pH 7.4))
-patient may be on both hyper-sal and pulmosal to help them! may switch to hyper-sal sometimes cuz it’s cheaper!)

21
Q

Pulmonary System: Mucus Alteration: 3. Mannitol inhalation powder (Bronchitol ®)

A
  • Osmotic agent, draws water into the airways, thins mucus
  • 18 years of age and older
  • Dry powder inhaler
  • Bronchitol ® tolerance test
  • Albuterol prior to use
  • Inhale contents of 10 capsules twice daily (faster than neb but a lot of work!)
  • Bronchospasm, hemoptysis
22
Q

Chronic Therapy - Pulmonary … other misc med

A

1.) Inhaled corticosteroids
– If patient also has asthma, not routinely used (do not use inhaled steroid for CF! does not work! it is used for asthma)
2.) Inhaled short-acting beta2-agonist
– Pre-treat with SABA for irritating inhaled
therapies

23
Q

Pulmonary System: the bacterial makeup

A

1.) Staphylococcus aureus: Major pathogen first year of life
2.) Haemophilus influenzae: Major pathogen by age 3 (at this time you will see a decrease in lung function)
3.) Pseudomonas aeruginosa: Major pathogen by age 5, Colonized
4.) Burkholderia, Stenotrophomonas, Aspergillus, MRSA
.
So we treat them with- Chronic antibiotics
– Intention is to prolong time between acute
exacerbations

24
Q

Chronic Therapy - Antibiotics: TOBI and Tobi® Podhaler®

A

TOBI® , TOBI® Podhaler®
– Nebulized and dry powder inhaler formulations of tobramycin
– P. aeruginosa colonization
– Given BID; 28 days on treatment, 28 days off (vacation to prevent resistance from developing)
.
Tobi® Podhaler® - dry powder
* 4 capsules (28 mg/capsule) inhaled BID
* Inhale 2 times from each capsule
* Take doses 12 hours apart
* Store capsules in blister card until ready to use
* Do not swallow capsules

25
Q

Chronic Therapy - Antibiotics: Cayston® (nebulized aztreonam)

A

– P. aeruginosa colonization
– Give TID; 28 days on treatment, 28 days off
– Altera nebulizer system
.
NOTE: usually start with TOBI but if symp progress then you may see them on this drug and other inhaled abx as well! Can switch inhaled abx around to prevent resistance)

26
Q

Sequence of Administering Inhaled Medications

A
  1. Bronchodilator (albuterol)
  2. Hypertonic saline - mucus adjust
  3. Pulmozyme® - mucus adjust
  4. Airway clearance technique - to cleared the adjusted mucus
  5. Aerosolized antibiotics
27
Q

Additional Systems the CF effects

A

Reproductive system
– Majority of males have congenital bilateral absence of the vas deferens
– Women are typically fertile but some have reduced fertility
.
Musculoskeletal system
– Decreased bone mineral density
– Malabsorption of vitamin D, poor nutritional status, corticosteroid use

28
Q

CFTR Modulator Class (newer promising drug!): 4 main classes - but focus on 2 of them because the other 2 are not approved in USA yet…what are they 2 approved ones and what drugs do they include? what do they do?

A

1.) Potentiators
– Ivacaftor
– Help open the CFTR channel and increase flux of
chloride and bicarbonate
2.) Correctors
– Elexacaftor, tezacaftor, lumacaftor
– Help normalize folding of CFTR and movement to cell
surface

29
Q

CFTR Modulator: Kalydeco™ (ivacaftor) - single potentiator: general, dosing, AE, warnings

A

– Targets the defective CFTR protein
– ≥ 4 months of age
– Patients with specific mutations: Not homozygous F508del aka from both mom and dad! (does not work in this but this is the most common mutation..)
– Improves Lung function, growth parameters, pulmonary exacerbations, reduces Pseudomonas aeruginosa
– Expensive, tablet form
.
Dosing
– Reduce dose in…
* Moderate-severe hepatic impairment
* CYP3A inhibitors: inhibitors: (e.g. ketoconazole, fluconazole): Adjust dose
* Avoid with strong inducer: e.g. carbamazepine, phenobarbital, phenytoin
* Avoid grapefruit
– Give with fat containing food
– Mix granules in 5 mL of soft food or liquid at or below room temperature (stable for 1 hour)
.
Warnings (for all CFTR modulators!!!!)
– May increase hepatic transaminases: Monitor liver function (Baseline, every 3 months during 1st year of therapy and yearly after)
– Cataracts
– CNS effects: dizziness, may impair abilities

30
Q

CFTR Modulator: Orkambi® (Lumacaftor + ivacaftor).. general, drug interaction, AE

A

Orkambi®
– a combination of Lumacaftor + ivacaftor
– 2 copies of F508del (yay! can be used in the more general pop.), ≥ 1 year of age
.
Drug interactions
– Lumacaftor strong inducer CYP3A: Avoid benzodiazepines, immunosuppressants
– Hormonal contraceptives: Decrease effectiveness
.
Respiratory AEs during initiation: Chest discomfort, dyspnea
.
NOTE: Not as impressive as Kalydeco tho when it was used in the population it was used in.

31
Q

CFTR Modulator: Symdeko®: medication components and population it is used it?

A

– Tezacaftor + ivacaftor tablet and ivacaftor tablet
– Co-packaged
* Tezacaftor 100mg/ivacaftor 150 mg fixed dose
combination tablet and ivacaftor 150 mg tablet
* Combination tablet in the morning, monotherapy
tablet in evening
– ≥6 years old with 2 copies of F508del or at
least one mutation that is responsive
- Not as expensive
.
NOTE: Not as impressive as Kalydeco tho when it was used in the population it was used in.

32
Q

CFTR Modulator: Trikafta™

A

– Elexacaftor + tezacaftor + ivacaftor
– ≥6 years old with at least one copy of F508del or mutation that is responsive
– Supplied as 2 separate products packaged together
…….. Elexacaftor/tezacaftor/ivacaftor
…….. Ivacaftor

33
Q

Acute Pulmonary Exacerbation: Signs and symptoms

A

– New or increased cough
– New or increased sputum production
– Change in sputum appearance
– Decreased exercise tolerance, decreased energy
– New or increased dyspnea with exertion
– Decreased pulmonary function tests
– Decreased appetite, weight
– Increased nasal congestion or drainage
– +/- Fever
– Chest x-ray not routinely done; may not show
changes over baseline